Skip to main content

Table 1 Demographic and clinical characteristics at second-line cART initiation stratified by HIV RNA level, 2000-2013

From: Outcomes of second-line combination antiretroviral therapy for HIV-infected patients: a cohort study from Rio de Janeiro, Brazil

   

HIV RNA level

 
  

Overall

Undetectable

Detectable

p-value

N (%)*

 

369

135

234

 

Age

     
 

Median (IQR)

38.3 (31.8-45.2)

38.7 (30.4-45.4)

37.9 (31.9-45.2)

0.93

 

≤30

78 (21.1)

33 (24.4)

45 (19.2)

0.27

 

30-39

127 (34.4)

40 (29.6)

87 (37.2)

 
 

≥40

164 (44.4)

62 (45.9)

102 (43.6)

 

Race

   

0.05

 

Non white

185 (50.1)

58 (43.0)

127 (54.3)

 
 

White

184 (49.9)

77 (57.0)

107 (45.7)

 

Gender/HIV exposure

   

0.28

 

Heterosexual men

110 (28.5)

36 (26.7)

70 (30.7)

 
 

Women

127 (33.0)

50 (37.0)

71 (31.1)

 
 

MSM

97 (25.0)

38 (28.1)

57 (25.0)

 
 

IDU

9 (2.5)

4 (3.0)

5 (2.2)

 
 

Other

37 (10.0)

7 (5.2)

25 (11.0)

 

Education

   

0.11

 

≤8 years

219 (59.5)

72 (53.7)

147 (62.8)

 
 

>8 years

149 (41.5)

62 (46.3)

87 (37.2)

 

Years since first HIV+ test

   

0.80

 

Median (IQR)

3.3 (1.8-5.8)

3.1 (1.7-5.8)

3.4 (1.9-5.7)

 

CD4 cell count, cells/mm3

   

<0.01

 

Median (IQR)

260 (145, 425)

412 (239, 617)

230 (118, 322)

 
 

≤200

110 (34.3)

19 (15.6)

91 (45.7)

 
 

201-350

96 (29.9)

31 (25.4)

65 (32.7)

 
 

>350

115 (35.8)

72 (59)

43 (21.6)

 

HIV RNA level*

   
 

Log10 copies/ml, median (IQR)

N/A

N/A

4.4 (3.8-5.0)

-

 

≤400 copies/ml

135 (36.6)

135 (100.0)

N/A

-

 

401-10,000 copies/ml

83 (22.5)

N/A

83 (35.5)

 
 

10,001-100,000 copies/ml

97 (26.3)

N/A

97 (41.5)

 
 

>100,000 copies/ml

54 (14.6)

N/A

54 (23.0)

 

Change in anchor drug from 1 st to 2 nd line

  

<0.01

 

NNRTI to PI-r

204 (55.3)

50 (37)

154 (65.8)

 
 

NNRTI to PI

27 (7.3)

13 (9.6)

14 (6)

 
 

PI/PI-r to NNRTI

73 (19.8)

42 (31.1)

31 (13.2)

 
 

PI/PI-r to PI/PI-r

65 (17.6)

30 (22.2)

35 (15)

 

Calendar year

   

0.97

 

2000-2006

154 (41.7)

57 (42.2)

97 (41.5)

 
 

2007-2013

215 (58.3)

78 (57.8)

137 (58.5)

 

Days from 1 st line failure to 2 nd line initiation

  

-

 

Median (IQR)

N/A

N/A

173 (0.0-606)

 
  1. *17 patients did not have an HIV RNA result prior to starting second-line cART.
  2. Abbreviations: HIV human immunodeficiency virus, MSM men who have sex with men, IDU injection drug user, ART antiretroviral therapy
  3. Gender and reported mode of HIV exposure were categorized jointly into women, heterosexual men, MSM, IDU (men and women) and other reported modes of HIV exposure (men and women). Individuals reporting both IDU and other modes of HIV exposure were categorized into IDU.
  4. Education was self-reported and based on the number of years of formal education.
  5. CD4 cell count was defined as the CD4 cell count closest to the date of start the second line cART up to 30 days after.
  6. HIV RNA was defined as the HIV RNA measurement closest to the date of start second line cART up to 7 days after.
  7. Days from failure of first-line cART to start of second-line cART was assumed to be zero if patients started second-line cART without virologic failure.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us